UniSuper Management Pty Ltd Acquires 4,328 Shares of IQVIA Holdings Inc. (NYSE:IQV)

UniSuper Management Pty Ltd grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 36.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,154 shares of the medical research company’s stock after buying an additional 4,328 shares during the period. UniSuper Management Pty Ltd’s holdings in IQVIA were worth $3,174,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Raymond James Financial Inc. bought a new position in IQVIA during the fourth quarter worth $236,120,000. American Century Companies Inc. boosted its position in shares of IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock worth $222,987,000 after purchasing an additional 905,960 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Nordea Investment Management AB increased its position in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares in the last quarter. Finally, KBC Group NV raised its stake in IQVIA by 68.5% during the 4th quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after buying an additional 250,458 shares during the period. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Bank of America reduced their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Morgan Stanley boosted their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Barclays lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Stephens began coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price for the company. Finally, UBS Group dropped their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Price Performance

Shares of NYSE:IQV opened at $177.27 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $176.03 and a fifty-two week high of $253.84. The company’s 50-day moving average is $193.15 and its 200 day moving average is $206.27. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $31.25 billion, a P/E ratio of 23.64, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.